BRUKER CORP

Nasdaq: BRKR·Billerica, Massachusetts·

Price
$60.62
Base IV
$29.56

Valuation snapshot

Above bull case

At $60.62, the price is above even our bull case of $45.97.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$29.56
49% of the price · range $9.74–$45.97
Price vs base case
105% above
$60.62 against $29.56
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has risen 4.4% since this valuation was struck on 2026-11-06, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $9.74 to bull $45.97. Values per share.

Price against each value

Bear case
$9.74
Price 522% above
No growth
…
—
Base case
$29.56
Price 105% above
Researched bygemini-3.8-flash-medium
Valuation Nov 6, 2026 · Price as of Nov 16, 2026How we got here

What does Bruker do?

It brought in $3.5B of sales in the 12 months to Sep 2026.

Bruker MALDI Biotyper mass spectrometerSpicy, CC BY-SA 4.0, via Wikimedia Commons
Industry
Semiconductors
Based in
Billerica, Massachusetts
Trades on
Nasdaq as BRKR

Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.04, so it lost 4¢ on each dollar. The biggest cost is making what it sells, 52¢ of every dollar.

$1 of sales
  • Making what it sells52¢
  • Research and development11¢
  • Sales, marketing and admin27¢
  • Everything else it takes to operate11¢
  • Tax1¢
  • Lost on each dollar−4¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Bruker, and for what?

Bruker develops, manufactures, and sells advanced scientific instruments and diagnostic systems. Customers use its equipment to examine molecules, cells, and microscopic materials in detail. The company generates revenue by selling these high-tech machines and providing ongoing maintenance, replacement parts, and software.

Customers include universities, government research agencies, pharmaceutical and biotechnology companies, hospitals, and industrial manufacturers.

  • BSI CALID

    35%

    Produces mass spectrometry, molecular spectroscopy, and diagnostic systems used in life science research, clinical microbiology, infectious disease testing, and food safety.

    Bruker MALDI Biotyper mass spectrometerSpicy, CC BY-SA 4.0, via Wikimedia Commons
  • BSI NANO

    32%

    Provides advanced X-ray tools, atomic force microscopes, optical imaging, and spatial biology systems to analyze materials and single cells at the nanoscale.

    Bruker D8 ADVANCE X-ray diffractometerImage: Bruker
  • BSI BioSpin

    26%

    Supplies magnetic resonance systems, including high-field nuclear magnetic resonance spectrometers and preclinical animal scanners, alongside laboratory automation software.

    Bruker Avance NEO NMR spectrometer systemImage: Bruker
  • BEST

    8%

    Manufactures metallic superconducting materials and specialized scientific tools used in clinical MRI machines, fusion energy projects, and particle physics research.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Bruker Fällanden site — Fällanden, Switzerland. This BSI BioSpin site supports magnetic resonance and preclinical imaging, and also houses a smaller leased BSI CALID mass spectrometry operation, so it underpins Bruker's high-end research instrument franchise.
  • Bruker Bremen mass spectrometry site — Bremen, Germany. At about 272,743 sq ft and owned, this is the largest clearly reported site in the 10-K property table and anchors mass spectrometry for the BSI CALID segment.
  • Bruker Hanau superconductor site — Hanau, Germany. This owned site of about 258,872 sq ft serves the energy and superconducting business, whose superconducting materials go to MRI, NMR and fusion energy research customers.
  • Bruker Ettlingen site — Ettlingen, Germany. Two owned facilities here, about 215,385 sq ft for BSI CALID mass spectrometry and CBRNE detection and about 179,399 sq ft for BSI BioSpin preclinical imaging, make it a multi-segment operating hub.
  • Bruker Wissembourg site — Wissembourg, France. This owned BSI BioSpin site of about 219,745 sq ft supports magnetic resonance and preclinical imaging, adding capacity to the segment's core product lines.
See them on the globe

Bruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025

How is the business doing?

Sales grew from $2B in 2020 to $3.4B in 2025, about 12% a year.

It spends more to run the business than it brings in: an operating loss of 2¢ per sales dollar.

After paying for its upkeep and new investment, it had $244.7M of cash to spare in the 12 months to Sep 2026.

Sales$3.4B
20162025
Operating margin2%
20162025
Free cash flow$43.3M
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Bruker aims to empower scientists and researchers to make breakthrough discoveries and create tools that improve human health and the environment.

“Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.”

Bruker About Us

What management says it is working on now:

Annualized cost savings, by the end of 2026
$120 million to $140 million
Bruker Reports Second Quarter 2026 Financial Results
Full-year revenue, FY 2026
$3.54 billion to $3.57 billion
Bruker Reports Second Quarter 2026 Financial Results
Organic revenue growth, FY 2026
1% to 2%
Bruker Reports Second Quarter 2026 Financial Results
Non-GAAP diluted EPS, FY 2026
$2.10 to $2.15
Bruker Reports Second Quarter 2026 Financial Results
Non-GAAP effective tax rate, FY 2026
approximately 27.5%
Bruker Reports Second Quarter 2026 Financial Results
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 2% more than a year earlier. The year before, quarters averaged 2%.

Its operating margin is narrower than a year ago: a loss of 10¢ per sales dollar, against a loss of 6¢.

Since Nov 2026 the share price has risen 9%, from $55.69 to $60.62.

Bull $45.97Base $29.56Bear $9.74Nov 3Nov 16 · $60.62
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start November 3, 2026.

Recently

Coming up

  • November 4, 2026

    Q3 2026 Earnings Announcement and Webcast

    Bruker will announce its third quarter 2026 operating results and discuss book-to-bill trends and full-year guidance adjustments.

    Bruker Investor Relations Events Calendar
  • End of 2026

    Completion of Corporate Cost Reduction Program

    The company expects to reach its annualized operational cost savings run rate of $120 million to $140 million across global functions.

    Bruker Reports Second Quarter 2026 Financial Results
  • Fourth quarter of 2026

    Semiconductor Metrology Deliveries Ramp

    Approximately $20 million of delayed semiconductor tool orders are scheduled to complete and deliver to customers, aiding fourth-quarter revenue.

    Bruker Second Quarter 2026 Earnings Conference Call

Our own estimate moved too: the base case went from $15.98 to $29.56 a share between our last two valuations. The biggest reason: Annual BSI CALID segment revenue moved from an unreported prior value to $1.1B, as reported in Bruker Corporation 2024 Form 10-K Note 18 Segment Information.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Import and Reciprocal Tariffs

    New and shifting tariffs increase manufacturing costs on imported parts and reduce customer purchasing power, which depresses gross margins and sales volumes.

    From the company's own filingsWould hit how much of each sale it keepsBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025

  2. Academic and Government Funding Reductions

    A substantial portion of customers depend on government research grants, and budget cuts or delays cause laboratories to postpone buying major instruments.

    From the company's own filingsWould hit how fast sales growBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025

  3. China Demand and Stimulus Delays

    Delays in the release of Chinese government stimulus spending for medical and industrial research instrumentation have dampened instrument sales growth in China.

    From the company's own filingsWould hit how fast sales growBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025

  4. Supply Chain and Single-Source Component Shortages

    The company relies on single-source suppliers for certain specialized components, and parts shortages or production delays create manufacturing inefficiencies and raise costs.

    From the company's own filingsWould hit how much of each sale it keepsBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025

  5. Goodwill and Intangible Asset Impairment

    Downturns in acquired businesses or higher market uncertainty can force write-downs of intangible assets, directly lowering reported operating profits.

    From the company's own filingsWould hit how much it has to reinvestBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025

  6. Rapid Technological Change and Competition

    If larger competitors develop faster, lower-cost, or more advanced analytical instruments, Bruker's products could become obsolete or lose pricing power.

    From the company's own filingsWould hit its growth in the long runBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025

  7. Revenue growth stalled to 2.08% in 2025 and 1.57% in Q3 2026 due to cyclical life sciences spending headwinds.

    From our researchWould hit how fast sales growBruker Q3 2026 Form 10-Q

  8. Q2 and Q3 2026 GAAP operating margins were -7.79% and -10.41% respectively, burdened by non-cash intangible asset amortization.

    From our researchWould hit how much of each sale it keepsBruker Q3 2026 Financial Release

Is it a good business?

From 2016 to 2025 it earned between 1% and 22% on the capital invested in it, a median of 18%. Its cost of capital in the latest valuation is 9.0%; returns were above it in 8 of the 10 years.

From 2016 to 2025 it earned between -0% and 31% on its shareholders' equity, a median of 21%.

Over 10 years its operating margin ranged from 2¢ to 17¢ per sales dollar, a median of 13¢. Gross margin ran from 46¢ to 52¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital1%
20162025

Cost of capital 9.0%

Return on equity-0%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 28%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It owes $1.6B more than it holds in cash. The latest four quarters had no positive operating profit to compare with that debt.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $60.62. Our put its value between $9.74 and $45.97, with $29.56 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $9.74

After significant acquisition spending and recent quarterly operating losses, this scenario assumes ongoing university and pharmaceutical budget constraints keep sales growth near 2% while profitability recovers only to high single-digit levels.

Base case, $29.56

This scenario anticipates that core demand for specialized scientific tools recovers to historical mid-single-digit sales growth while aggressive operational cost savings return profitability to healthy mid-teen levels.

Bull case, $45.97

This scenario envisions a strong rebound fueled by expanding biotechnology budgets and rapid commercial scaling in spatial biology and automated diagnostics, lifting profitability back toward 19%.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 105%

For Bruker to be worth today's $60.62, sales would need to grow about 19.7% a year. We assume 5.6%. Over the last 5 years, sales grew 8.3% a year.

−5%0%+5%+10%+15%+20%+25%We assume 5.6%Past 5 yrs 8.3%Price needs 19.7%

Or, if sales grow 5.6% as we assume, the price works with a profit margin of 27.5% (we assume 15.5%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 19.7% a year?

Try your own numbers

We're moderately sure of this range: it scores 59 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $29.56 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average5.6%
  • Operating margin15.5%
  • Long-term growth rate3.0%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$29.56 -51.2%

Build